间充质干细胞
肾脏疾病
生物
细胞外小泡
肾
急性肾损伤
疾病
肾干细胞
肾病科
胞外囊泡
微泡
干细胞
生物信息学
免疫学
癌症研究
病理
医学
内科学
小RNA
祖细胞
内分泌学
细胞生物学
基因
生物化学
作者
Enhui Li,Jia Xu,Ning Liu,Xiong Qi,Wei Zhang,Yizi Gong,Linlin Zhang,Yikai He,Huipeng Ge,Xiangcheng Xiao
出处
期刊:Stem Cells
[Wiley]
日期:2023-11-30
卷期号:42 (3): 216-229
被引量:1
标识
DOI:10.1093/stmcls/sxad089
摘要
The high prevalence and complex etiology of renal diseases already impose a heavy disease burden on patients and society. In certain kidney diseases such as acute kidney injury and chronic kidney disease, current treatments are limited to slowing rather than stabilizing or reversing disease progression. Therefore, it is crucial to study the pathological mechanisms of kidney disease and discover new therapeutic targets and effective therapeutic drugs. As cell-free therapeutic strategies are continually being developed, extracellular vesicles derived from mesenchymal stem cells (MSC-EVs) have emerged as a hot topic for research in the field of renal diseases. Studies have demonstrated that MSC-EVs not only reproduce the therapeutic effects of MSCs but also localize to damaged kidney tissue. Compared to MSCs, MSC-EVs have several advantages, including ease of preservation, low immunogenicity, an inability to directly form tumors, and ease of artificial modification. Exploring the detailed mechanisms of MSC-EVs by developing standardized culture, isolation, purification, and drug delivery strategies will help facilitate their clinical application in kidney diseases. Here, we provide a comprehensive overview of studies about MSC-EVs in kidney diseases and discuss their limitations at the human nephrology level.
科研通智能强力驱动
Strongly Powered by AbleSci AI